National Health Investors, Inc. (NYSE:NHI) – Capital One Financial issued their Q1 2022 earnings estimates for shares of National Health Investors in a report released on Tuesday, March 30th. Capital One Financial analyst D. Bernstein expects that the real estate investment trust will post earnings per share of $1.26 for the quarter. Capital One Financial has a “Equal Weight” rating and a $77.00 price target on the stock. Capital One Financial also issued estimates for National Health Investors’ Q3 2022 earnings at $1.33 EPS and FY2022 earnings at $5.29 EPS. National Health Investors (NYSE:NHI) last issued its earnings results on Sunday, February 21st. The real estate investment trust reported $0.82 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.01 by ($0.19). The company had revenue of $81.24 million during the quarter, compared to analysts’ expectations of $84.22 million. National Health Investors had a net margin of 56.94% and a return on equity of 12.64%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.41 earnings per share.
NHI has been the subject of a number of other reports. BMO Capital Markets cut National Health Investors from a “market perform” rating to an “underperform” rating and set a $68.00 price target for the company. in a report on Thursday, January 7th. Berenberg Bank lowered National Health Investors from a “buy” rating to a “hold” rating in a research report on Wednesday, December 2nd. Zacks Investment Research lowered National Health Investors from a “hold” rating to a “sell” rating in a research report on Wednesday, February 24th. Truist Securities increased their price target on National Health Investors from $69.00 to $74.00 in a research report on Tuesday, March 23rd. Finally, Truist increased their price target on National Health Investors from $69.00 to $74.00 in a research report on Tuesday, March 23rd. Three equities research analysts have rated the stock with a sell rating and seven have given a hold rating to the company. National Health Investors currently has a consensus rating of “Hold” and a consensus target price of $65.60.
Sales in the Cannabis sector are set to increase from $10 billion in 2018 to an estimated $97 billion by 2026, according to a new report from Fortune Business Insights …
Not only that, current advances in production and distribution technology are boosting margins and bringing huge profits to early investors.
NYSE NHI opened at $72.28 on Thursday. The stock has a market cap of $3.29 billion, a PE ratio of 16.97 and a beta of 0.88. The company has a current ratio of 13.13, a quick ratio of 13.13 and a debt-to-equity ratio of 1.02. National Health Investors has a twelve month low of $36.61 and a twelve month high of $78.56. The stock has a fifty day simple moving average of $71.85 and a 200-day simple moving average of $66.15.
Several hedge funds and other institutional investors have recently modified their holdings of NHI. Marshall Wace North America L.P. acquired a new stake in shares of National Health Investors during the 1st quarter worth about $31,000. International Assets Investment Management LLC acquired a new stake in shares of National Health Investors during the 4th quarter worth about $32,000. Van ECK Associates Corp raised its position in shares of National Health Investors by 23.5% during the 3rd quarter. Van ECK Associates Corp now owns 1,298 shares of the real estate investment trust’s stock worth $78,000 after acquiring an additional 247 shares in the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new position in National Health Investors during the 4th quarter worth approximately $183,000. Finally, Shayne & CO. LLC purchased a new position in National Health Investors during the 4th quarter worth approximately $214,000. 65.72% of the stock is currently owned by institutional investors and hedge funds.
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 7th. Stockholders of record on Wednesday, March 31st will be given a dividend of $1.102 per share. This represents a $4.41 annualized dividend and a dividend yield of 6.10%. The ex-dividend date is Tuesday, March 30th. National Health Investors’s dividend payout ratio (DPR) is presently 80.18%.
About National Health Investors
Incorporated in 1991, National Health Investors, Inc (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI’s portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals.
Read More: Why is insider trading harmful?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
To say it’s been a rough two years for the cannabis industry is an understatement. Due to a combination of issues (including some self-inflicted wounds), the cannabis boom predicted in 2018 has not materialized. But that could be about to change.
If Joe Biden wins the presidential election, it will likely be part of a “Blue Wave” that will bring Democratic party control of both houses of Congress. And even if President Trump successfully wins a second term, it is still possible that Republicans could lose their hold on the Senate.
The bottom line is there is a range of outcomes that are possible. Most of those outcomes are favorable to the legalization of marijuana. And even if cannabis is not made legal on the federal level, it seems likely that the remaining states holding out will take steps to legalization. That’s because, like gambling, cannabis may create an economic lift that cash-strapped states may find too difficult to turn down.
One thing is certain. If you wait until the right time, you’ll have missed out on some eye-popping initial gains. But to get that reward in the future, you’ll need to assume some risk now. In this special presentation, we’ve identified seven cannabis stocks that you can consider when evaluating your opportunity in the cannabis sector.